Our recent activity

Agomab Therapeutics Completes Acquisition of Origo Biopharma

Agomab Therapeutics NV (‘Agomab’) announced today the closing of the Origo Biopharma acquisition. The transaction, first announced on October 28th, 2021, combines Spanish biotech Origo Biopharma and its pipeline of organ-restricted small molecule drug candidates targeting the transforming growth factor beta (TGF-β) pathway with Agomab’s hepatocyte growth factor (HGF)-targeting programs. The merged company will focus on developing therapeutics that translate growth factor signaling pathways into innovative therapies for the treatment of fibrosis related diseases.

“Through this acquisition, we have taken a big step in broadening our clinical-stage pipeline and are ultimately one step closer to bringing meaningful treatments to patients with fibrotic diseases. The synergies between Origo’s unique small molecule platform and Agomab’s antibody capabilities, combined with our collective expertise in targeting growth factors, will allow us to accelerate the development of novel therapeutic candidates,” said Paul van der Horst, Chief Business Officer at Agomab Therapeutics. “We would like to thank all the parties who have supported the completion of this transaction.”

Agomab will integrate the full Origo team as well as its facilities in Touro and Barcelona in Spain into its current organization, complimenting Agomab’s headquarters in Belgium and research laboratories in Italy.

About Agomab

Agomab is translating a deep expertise in growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure and restore organ function. Combining new scientific insights with robust drug development and a long-term corporate vision, we are building a broad clinical pipeline of differentiated programs with disease modifying potential in severe organ failure and fibrotic diseases.

Internal
September 15, 2022

Asabys launches a new €200m fund to invest in biotech & healthtech

READ THIS NEWS IN SPANISH The fund’s first closing is expected by the end of this year, with commitments from institutional and private investors such as Banc Sabadell and the…
Portfolio
September 13, 2022

Agomab Therapeutics Selected as One of Fierce Biotech’s “Fierce 15” Companies of 2022

Agomab Therapeutics NV (‘Agomab’) today announced that Fierce Biotech has named the company as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage…
Portfolio
July 13, 2022

Agomab Raises Additional $40.5 Million Through Series B Extension Bringing Total Amount to $114M

READ THIS NEWS IN SPANISH ● Extension led by Pfizer with participation from new investors Walleye Capital and Asabys Partners as well as existing investors ● Funding will support next…